<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827004</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-20-II</org_study_id>
    <nct_id>NCT04827004</nct_id>
  </id_info>
  <brief_title>A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Open-label, Single-center, Single-arm Phase II Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-center, single-arm study to evaluate the efficacy and safety of&#xD;
      Anlotinib Hydrochloride Capsules in subjects with diffuse large B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>PFS defined as the time from first medication until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib Hydrochloride Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a multi-target receptor tyrosine kinase inhibitor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride Capsules</intervention_name>
    <description>Anlotinib capsules given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
    <arm_group_label>Anlotinib Hydrochloride Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. ≥18 years old; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or&#xD;
             1, life expectancy≥ 12 weeks.&#xD;
&#xD;
             2. Histopathologically confirmed diffuse large B-cell lymphoma (DLBCL) . 3. Has&#xD;
             received at least 2 lines of systemic treatment. 4. At least one measurable lesion in&#xD;
             vertical directions(based on Lugano 2014). 5.Adequate organ system function. 6. Male&#xD;
             or female subjects should agree to use an adequate method of contraception starting&#xD;
             with the first dose of study therapy through 6 months after the last dose of study&#xD;
             (such as intrauterine devices , contraceptives or condoms) ; No pregnant or&#xD;
             breastfeeding women, and a negative pregnancy test are received within 7 days before&#xD;
             the randomization.&#xD;
&#xD;
             7. Understood and signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. DLBCL transformed from indolent lymphoma (such as FL), primary testicular DLBCL,&#xD;
             primary central nervous system lymphoma, mixed lymphoma (such as B cell lymphoma that&#xD;
             cannot be classified between HL and DLBCL) Tumor, etc.), Richter's transformed DLBCL.&#xD;
&#xD;
             2. Has central nervous system (CNS) invasion. 3. Has received vascular endothelial&#xD;
             growth inhibitor, such as sunitinib, sorafenib, pazopanib, imatinib, famitinib,&#xD;
             apatinib, anlotinib and so on.&#xD;
&#xD;
             4. Has other malignancies (except cured skin basal cell carcinoma and cervical&#xD;
             carcinoma in situ) within 3 years.&#xD;
&#xD;
             5. Has a history of immunodeficiency. 6. Has multiple factors affecting oral&#xD;
             medication. 7.Has uncontrollable or important cardiovascular disease. 8.Has any severe&#xD;
             and/or uncontrolled diseases. 9. Has received surgery, or unhealed wounds within 4&#xD;
             weeks before the first administration.&#xD;
&#xD;
             10. Has received systemic steroid therapy within 7 days before the first&#xD;
             administration.&#xD;
&#xD;
             11. Imaging (CT or MRI) shows that tumor invades large blood vessels or the boundary&#xD;
             with blood vessels is unclear.&#xD;
&#xD;
             12. Has any bleeding symptoms or treated with anticoagulants or vitamin K antagonists.&#xD;
&#xD;
             13. Has arterial or venous thromboembolic events occurred within 6 months, such as&#xD;
             cerebrovascular accident including transient ischemic attack, deep vein thrombosis and&#xD;
             pulmonary embolism.&#xD;
&#xD;
             14. Has psychotropic substances abuse or a mental disorder. 15. Has received&#xD;
             autologous hematopoietic stem cell transplantation within 3 months before the first&#xD;
             administration, or have received allogeneic hematopoietic stem cell transplantation,&#xD;
             or have graft-versus-host reaction.&#xD;
&#xD;
             16. Has received other anti-tumor therapy within 4 weeks before the first&#xD;
             administration.&#xD;
&#xD;
             17.According to the judgement of the researchers, there are other factors that may&#xD;
             lead to the termination of the study.&#xD;
&#xD;
             18. Unsuitable for anlotinib hydrochloride.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuankai Shi, Doctor</last_name>
    <phone>010-87788268</phone>
    <email>syuankaipumc@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuankai Shi, Doctor</last_name>
      <phone>010-87788268</phone>
      <email>syuankaipumc@126.com</email>
    </contact>
    <investigator>
      <last_name>Yuankai Shi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

